Equillium (EQ) Common Equity (2017 - 2026)
Equillium (EQ) posted quarterly Common Equity of $59.5 million for Q1 2026, up 462.37% year-over-year from $10.6 million in Q1 2025, and up 108.02% quarter-over-quarter from $28.6 million in Q4 2025.
Equillium (EQ) Common Equity (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Common Equity for 10 consecutive years, with $59.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 462.37% year-over-year to $59.5 million; the TTM figure through Mar 2026 stood at $59.5 million (up 462.37% YoY), while the FY2025 annual figure was $28.6 million, up 50.03% from the prior year.
- Common Equity climbed to $59.5 million in Q1 2026 per EQ's latest filing, from $28.6 million in the prior quarter.
- Across five years, Common Equity topped out at $59.5 million in Q1 2026 and bottomed at $5.1 million in Q2 2025.
- Historically, Common Equity has averaged $28.0 million across 5 years, with a median of $27.0 million in 2023.
- Annual changes were most pronounced in 2025 — Common Equity tumbled 77.46% — and 2026, when it surged 462.37%.
- Equillium's Common Equity stood at $31.9 million in 2022, then decreased by 29.33% to $22.6 million in 2023, then dropped by 15.56% to $19.1 million in 2024, then jumped by 50.03% to $28.6 million in 2025, then jumped by 108.02% to $59.5 million in 2026.
- Business Quant data shows EQ's Common Equity at $59.5 million in Q1 2026, $28.6 million in Q4 2025, and $30.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 56.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.02 Mn |
| Mar 31, 2026 | 59.49 Mn |
| Dec 31, 2025 | 28.60 Mn |
| Sep 30, 2025 | 30.94 Mn |
| Jun 30, 2025 | 5.06 Mn |
| Mar 31, 2025 | 10.58 Mn |
| Dec 31, 2024 | 19.06 Mn |
| Sep 30, 2024 | 23.18 Mn |
| Jun 30, 2024 | 22.43 Mn |
| Mar 31, 2024 | 21.09 Mn |
| Dec 31, 2023 | 22.57 Mn |
| Sep 30, 2023 | 24.11 Mn |
| Jun 30, 2023 | 26.98 Mn |
| Mar 31, 2023 | 29.27 Mn |
| Dec 31, 2022 | 31.94 Mn |
| Sep 30, 2022 | 28.16 Mn |
| Jun 30, 2022 | 40.27 Mn |
| Mar 31, 2022 | 52.63 Mn |
| Dec 31, 2021 | 66.51 Mn |
| Sep 30, 2021 | 75.80 Mn |